RESUMO
RATIONALE: The innate immune response contributes to cardiac injury in myocardial ischemia/reperfusion (MI/R). Neutrophils are an important early part of the innate immune response to MI/R. Adenosine, an endogenous purine, is a known innate immune modulator and inhibitor of neutrophil activation. However, its delivery to the heart is limited by its short half-life (<30 s) and off-target side effects. CD39 and CD73 are anti-inflammatory homeostatic enzymes that can generate adenosine from phosphorylated adenosine substrate such as ATP released from injured tissue. OBJECTIVE: We hypothesize that hydrogel-delivered CD39 and CD73 target the local early innate immune response, reduce neutrophil activation, and preserve cardiac function in MI/R injury. METHODS AND RESULTS: We engineered a poly(ethylene) glycol (PEG) hydrogel loaded with the adenosine-generating enzymes CD39 and CD73. We incubated the hydrogels with neutrophils in vitro and showed a reduction in hydrogen peroxide production using Amplex Red. We demonstrated availability of substrate for the enzymes in the myocardium in MI/R by LC/MS, and tested release kinetics from the hydrogel. On echocardiography, global longitudinal strain (GLS) was preserved in MI/R hearts treated with the loaded hydrogel. Delivery of purinergic enzymes via this synthetic hydrogel resulted in lower innate immune infiltration into the myocardium post-MI/R, decreased markers of macrophage and neutrophil activation (NETosis), and decreased leukocyte-platelet complexes in circulation. CONCLUSIONS: In a rat model of MI/R injury, CD39 and CD73 delivered via a hydrogel preserve cardiac function by modulating the innate immune response.
Assuntos
Isquemia Miocárdica , Traumatismo por Reperfusão Miocárdica , Ratos , Animais , Hidrogéis/uso terapêutico , Coração , Miocárdio , Adenosina , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Polietilenoglicóis/uso terapêuticoRESUMO
[Figure: see text].
Assuntos
5'-Nucleotidase/administração & dosagem , Adenosina/metabolismo , Portadores de Fármacos , Membro Posterior/irrigação sanguínea , Isquemia/tratamento farmacológico , Maleimidas/química , Doença Arterial Periférica/tratamento farmacológico , Polietilenoglicóis/química , 5'-Nucleotidase/química , 5'-Nucleotidase/metabolismo , Animais , Células Cultivadas , Preparações de Ação Retardada , Modelos Animais de Doenças , Composição de Medicamentos , Feminino , Humanos , Hidrogéis , Isquemia/enzimologia , Isquemia/fisiopatologia , Masculino , Camundongos Endogâmicos C57BL , Ativação de Neutrófilo/efeitos dos fármacos , Doença Arterial Periférica/enzimologia , Doença Arterial Periférica/fisiopatologia , Fluxo Sanguíneo Regional , Regulação para CimaRESUMO
For cell therapies, the subcutaneous space is an attractive transplant site due to its large surface area and accessibility for implantation, monitoring, biopsy, and retrieval. However, its poor vascularization has catalyzed research to induce blood vessel formation within the site to enhance cell revascularization and survival. Most studies focus on the subcutaneous space of rodents, which does not recapitulate important anatomical features and vascularization responses of humans. Herein, we evaluate biomaterial-driven vascularization in the porcine subcutaneous space. Additionally, we report the first use of cost-effective fluorescent microspheres to quantify perfusion in the porcine subcutaneous space. We investigate the vascularization-inducing efficacy of vascular endothelial growth factor (VEGF)-delivering synthetic hydrogels based on 4-arm poly(ethylene) glycol macromers with terminal maleimides (PEG-4MAL). We compare three groups: a non-degradable hydrogel with a VEGF-releasing PEG-4MAL gel coating (Core+VEGF gel); an uncoated, non-degradable hydrogel (Core-only); and naïve tissue. After 2 weeks, Core+VEGF gel has significantly higher tissue perfusion, blood vessel area, blood vessel density, and number of vessels compared to both Core-only and naïve tissue. Furthermore, healthy vital signs during surgery and post-procedure metrics demonstrate the safety of hydrogel delivery. We demonstrate that VEGF-delivering synthetic hydrogels induce robust vascularization and perfusion in the porcine subcutaneous space.
Assuntos
Materiais Biocompatíveis , Fator A de Crescimento do Endotélio Vascular , Humanos , Suínos , Animais , Fator A de Crescimento do Endotélio Vascular/farmacologia , Materiais Biocompatíveis/metabolismo , Hidrogéis/farmacologia , Hidrogéis/metabolismo , PolietilenoglicóisRESUMO
BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although treatment options for AF exist, many patients cannot be maintained in normal sinus rhythm. Amiodarone is an effective medication for AF but has limited clinical utility because of off-target tissue toxicity. METHODS: Here, we use a pig model of AF to test the efficacy of an amiodarone-containing polyethylene glycol-based hydrogel. The gel is placed directly on the atrial epicardium through the pericardial space in a minimally invasive procedure using a specially designed catheter. RESULTS: Implantation of amiodarone-containing gel significantly reduced the duration of sustained AF at 21 and 28 days; inducibility of AF was reduced 14 and 21 days post-delivery. Off-target organ drug levels in the liver, lungs, thyroid, and fat were significantly reduced in animals treated with epicardial amiodarone gel compared with systemic controls in small-animal distribution studies. CONCLUSIONS: The pericardium is an underutilized therapeutic site and may be a new treatment strategy for AF and other cardiovascular diseases.
Assuntos
Amiodarona/administração & dosagem , Antiarrítmicos/administração & dosagem , Fibrilação Atrial/prevenção & controle , Portadores de Fármacos , Frequência Cardíaca/efeitos dos fármacos , Pericárdio/efeitos dos fármacos , Polietilenoglicóis/química , Amiodarona/química , Amiodarona/toxicidade , Animais , Antiarrítmicos/química , Antiarrítmicos/toxicidade , Fibrilação Atrial/fisiopatologia , Modelos Animais de Doenças , Composição de Medicamentos , Implantes de Medicamento , Liberação Controlada de Fármacos , Hidrogéis , Masculino , Pericárdio/fisiopatologia , Ratos Sprague-Dawley , Sus scrofa , Fatores de TempoRESUMO
Targeting drugs and nanoparticles to cardiomyocytes has been an elusive challenge. Cardiomyocytes are inherently non-phagocytic and their environment is subjected to contractile forces which tend to expel injected and catheter-delivered drugs. In this issue, a novel-targeting strategy, N-acetyl-glucosamine (GlcNAc) coating, is shown to enhance cardiomyocyte nanoparticle uptake both in vitro and in vivo. Many effective and proven therapies for myocardial infarction are in clinical use thus raising the bar for the translation of new technologies. Nevertheless, GlcNAc targeting represents a promising approach for improved targeting of drug therapies to cardiomyocytes.